SCHEMBL4888172

SCHEMBL4888172

O=c1c2ccccc2ccn1-c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
MGLL Q99685 1/20 0.46
NTRK1 P04629 1/20 0.42
IGF1R P08069 1/20 0.42
FGFR1 P11362 1/20 0.42
NTRK3 Q16288 1/20 0.42
NTRK2 Q16620 1/20 0.42
SCN9A Q15858 4/20 0.42
PGR P06401 1/20 0.40
PLCG1 P19174 1/20 0.39
KAT2B Q92831 1/20 0.39
IDH1 O75874 1/20 0.38
PIM1 P11309 1/20 0.38
GSTP1 P09211 1/20 0.38
LTA4H P09960 1/20 0.38
TSHR P16473 1/20 0.38
PSMB1 P20618 1/20 0.38
PSMB2 P49721 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593323 0.85 KDM4E (0.47) KDM4EALDH1A1PGRTSHR
SCHEMBL29431541 0.85 KDM4E (0.47) KDM4EALDH1A1PGRTSHR
SCHEMBL30034874 0.84 MAPT (0.55) KDM4EALDH1A1RXFP1
SCHEMBL28582077 0.84 MAPT (0.55) KDM4EALDH1A1RXFP1
SCHEMBL13659161 0.79 NPC1 (0.54) KDM4EKAT2B
SCHEMBL20887040 0.79 BIRC5 (0.39) KDM4EALDH1A1MGLL
SCHEMBL20887041 0.79 BIRC5 (0.59) KDM4EALDH1A1RXFP1TSHR
SCHEMBL20887039 0.79 LMNA (0.51) KDM4EALDH1A1
SCHEMBL15525421 0.79 ESR1 (0.46) KDM4EALDH1A1
SCHEMBL29809422 0.79 METAP2 (0.49) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents EXELIXIS, INC. (US) 2008-06-05 US disclosed
US-7265131-B2 Isoquinolinone derivatives and their use as therapeutic agents EXELIXIS, INC. (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132521-A1 Isoquinolinone Derivatives and Their Use As Therapeutic Agents NR1H2, NR1H3, NR1I2 KDM4E 3727/4885ALDH1A1 601/4885RXFP1 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.